A preparation method of ponatinib hydrochloride crystal form A
By using a combination method of ketone or ester solvent and hydrochloric acid in the preparation of ponatinib hydrochloride A crystal form, the process flow is simplified, the process complex process and solvent residue problems in the prior art are solved, and high purity and high purity are achieved The preparation of the A crystal form of ponatinib hydrochloride in yield is suitable for pharmaceutical standards.
Patent Information
- Application Number
- CN202310308725.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-03-27
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2043-03-27
AI Technical Summary
The existing preparation process of ponatinib hydrochloride A crystal form is complex, the solvent residue is difficult to control, the fluidity is poor and the yield is low, and the solvent used is unfriendly to the environment and difficult to meet the pharmaceutical standards.
Ponatinib free alkali is heated and dissolved in ketones or ester solvents, hydrochloric acid is added dropwise, crystallization is analyzed by stirring and cooling, and then filtering and drying. Decompression or blowing drying technology is used to obtain high-purity Ponatin hydrochloric acid. Tinib A crystal form simplifies the process flow and reduces solvent residue.
It has achieved good reproducibility, excellent product quality, simple process, green and environmentally friendly and high yield, suitable for industrial production, low solvent residue, and meets pharmaceutical standards.
Smart Images

Figure BDA0004147741160000011 
Figure BDA0004147741160000031 
Figure HDA0004147741190000011
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of drug synthesis, and specifically relates to a method for preparing ponatinib hydrochloride crystal form A Background Art
[0002] Ponatinib hydrochloride, chemical name: 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide, hydrochloride, structural formula is as follows:
[0003]
[0004] Ponatinib tablets were first approved by the US FDA for accelerated marketing in December 2012, but sales were suspended in October 2013 due to the risk of "serious and fatal thrombosis and vascular stenosis". In December 2013, the FDA conducted a risk-benefit assessment and approved it for marketing again under safety monitoring. The EU and Japan were approved in July 2013 and September 2016, respectively.
[0005] Ponatinib hydrochloride is currently approved by the US FDA for: ① CP-CML (chronic phase chronic myeloid leukemia) resistant or intolerant to at least two previous kinase inhibitors; ② AP-CML (accelerated phase chronic myeloid leukemia), BP-CML (blast phase chronic myeloid leukemia), and Ph+ALL (Philadelphia chromosome-positive acute lymphoblastic leukemia) without other kinase inhibitor indications. Ponatinib belongs to the third generation of BCR-ABL tyrosine kinase inhibitors (TKIs), which can effectively inhibit wild-type and mutant BCR-ABL (including T315I mutations), and can also widely inhibit other tyrosine kinase families such as VEGFR, PDGFR, FGFR, FLT3 and KIT.
[0006] Patent CN105188701A discloses a method for preparing crystal form A of ponatinib hydrochloride, in which the starting raw material to be used must be a specific crystal form A free base, ethanol is used as a solvent for salt formation, and seed crystals need to be added to prepare crystal form A of ponatinib hydrochloride, and the residual ethanol is 0.85%. This method has the following shortcomings: ① The crystallization method is complex, requiring five steps of cooling evaporation, anti-solvent addition, grinding, slurrying and steam diffusion; ② This method must use crystal form A to crystallize in ethanol to obtain crystal form A; ③ The residual ethanol is difficult to control to less than 0.5%; ④ ponatinib free base requires a specific crystal form A.
[0007] Patent CN104496994 A discloses a preparation process of ponatinib hydrochloride α-crystalline form, wherein acetonitrile is heated and then hydrochloric acid is added dropwise and stirred in ethanol to prepare ponatinib hydrochloride α-crystalline form. This method uses acetonitrile, a Class II solvent that is environmentally unfriendly and highly toxic. By reproducing the preparation process of the patent, it was found that: ponatinib free base has poor solubility in acetonitrile, the acetonitrile residue seriously exceeds the standard, and the obtained ponatinib hydrochloride α-crystalline form has poor fluidity and large static electricity, so it is not suitable for medicinal use. Summary of the invention
[0008] In order to overcome the shortcomings of the prior art of the complex preparation process of ponatinib hydrochloride form A, high residual solubility, poor fluidity and low yield, the object of the present invention is to provide a preparation method of ponatinib hydrochloride form A which has good reproducibility, excellent product quality, simple preparation process, green and environmental protection, high yield and is suitable for industrial scale-up production.
[0009] The preparation method of ponatinib hydrochloride crystal form A provided by the present invention comprises the following steps:
[0010] S1: heating and dissolving ponatinib free base in a ketone solvent or an ester solvent;
[0011] S2: adding hydrochloric acid to form salt;
[0012] S3: stirring, cooling and crystallizing, filtering or centrifuging, and drying to obtain ponatinib hydrochloride crystal form A.
[0013] Further, the ketone solvent in S1 is selected from acetone or 2-butanone; the ester solvent is selected from methyl formate, methyl acetate, ethyl acetate, propyl acetate, isopropyl acetate, isobutyl acetate or butyl acetate;
[0014] Further, the ketone or ester solvent is selected from one or more of acetone, 2-butanone, methyl formate, methyl acetate, ethyl acetate, propyl acetate, isopropyl acetate, isobutyl acetate or butyl acetate;
[0015] Further preferably, the ketone solvent is selected from acetone; the ester solvent is selected from ethyl acetate;
[0016] Furthermore, the mass volume ratio of ponatinib free base to ketone solvent or ester solvent in S1 is 1:20 to 1:50 g / mL, preferably 1:20 to 1:30 g / mL, and more preferably 1:25 g / mL.
[0017] The molar ratio of ponatinib free base to hydrochloric acid in S2 is 1:0.8-1.1, preferably 1:0.98.
[0018] As a preferred embodiment, an amide solvent, an alcohol solvent or water may be added in step S2;
[0019] Further, in the preferred embodiment of S2, the amide solvent is selected from N,N-dimethylformamide, N,N-dimethylacetamide or N-methylpyrrolidone; the alcohol solvent is selected from ethanol, methanol, n-propanol or isopropanol;
[0020] Furthermore, the mass volume ratio of the ponatinib free base to the amide solvent, alcohol solvent or water is 1:1 to 1:5 g / mL, preferably 1:1 g / mL.
[0021] The salt formation temperature in S2 is 50-80°C, preferably 50-60°C, more preferably 50°C;
[0022] Furthermore, the crystallization time in S3 is 2±0.5h.
[0023] Furthermore, the drying method is reduced pressure drying or forced air drying; the drying temperature is 65 to 95° C., preferably 65 to 75° C.; and the drying time is 10 to 20 hours.
[0024] Furthermore, the drying method is preferably reduced-pressure drying, with a vacuum degree of -0.080 to -0.095 MPa, a drying temperature of 75° C., and a drying time of 16 hours.
[0025] Furthermore, the preparation method of the ponatinib hydrochloride crystal form A comprises the following steps:
[0026] The ponatinib free base is heated and dissolved in acetone or ethyl acetate, and then hydrochloric acid is added dropwise. After stirring for 30 minutes, the temperature is lowered to 50°C for crystallization. After stirring at 50°C for 2 hours, the temperature is lowered to room temperature. After keeping the temperature and stirring for 2 hours, the mixture is filtered and dried at 75°C in vacuum to obtain ponatinib hydrochloride crystal form A.
[0027] Beneficial effects achieved by the present invention:
[0028] (1) The process of the present invention is simple, and only needs to use ponatinib free base and hydrochloric acid to form a salt, and then cool and crystallize to obtain ponatinib hydrochloride A crystal form, and the entire reaction can be completed in one step;
[0029] (2) The requirements for reaction equipment are not high, and the solvents used are safe and have low toxicity;
[0030] (3) Ponatinib free base does not require a specific crystal form, and ponatinib hydrochloride crystal form A can be prepared without adding seed crystals. The obtained crystal form A has high purity and low solvent residue, meets pharmaceutical standards, and the yield can reach more than 90%, which is suitable for industrial production. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] Figure 1 This is the XRD pattern of ponatinib hydrochloride Form A. DETAILED DESCRIPTION
[0032] The present invention is further described in detail below in conjunction with the embodiments, but the present invention is not limited thereto. Any equivalent substitutions in the art made according to the disclosure of the present invention shall fall within the protection scope of the present invention.
[0033] XRD: X-ray powder diffraction
[0034] The X-ray powder diffraction (XRD) test described in this application is collected using a Malvern Panalytical Empyrea powder diffractometer, and the specific parameters are as follows:
[0035]
[0036] Example 1 Preparation of Ponatinib Hydrochloride Crystal Form A
[0037] Take 5.0g of ponatinib free base, heat and dissolve it in 125ml of acetone, then add 0.88g of hydrochloric acid dropwise, stir for 30 minutes, cool to 50℃ for crystallization, stir at 50℃ for 2 hours, cool to room temperature, keep warm and stir for 2 hours, filter, and wash the filter cake with acetone. Dry at 75℃ in vacuum to obtain 4.95g of yellow solid, with a yield of 92.7%. The solvent residue of acetone is 0.26%. The obtained solid is subjected to X-ray powder determination using Cu-ka ray, and its XRD spectrum is as follows Figure 1 shown.
[0038] Example 2 Preparation of Ponatinib Hydrochloride Crystal Form A
[0039] Take 5.0g of ponatinib free base, heat and dissolve it in 125mL of ethyl acetate, then add 0.88g of hydrochloric acid dropwise, stir for 30 minutes, cool to 50°C for crystallization, stir at 50°C for 2 hours, cool to room temperature, keep warm and stir for 2 hours, filter, and wash the filter cake with ethyl acetate. Dry at 75°C in vacuum to obtain 4.79g of yellow solid, with a yield of 90.7%, and the solvent residue of ethyl acetate is 0.25%. The obtained XRD spectrum is consistent with that in Example 1.
[0040] Example 3 Preparation of Ponatinib Hydrochloride Crystal Form A
[0041] Take 5.0g of ponatinib free base, heat and dissolve it in 150mL of acetone, then dropwise add 0.88g of hydrochloric acid and 3.5mL of N,N-dimethylformamide, stir for 30 minutes, cool to 50°C for crystallization, stir at 50°C for 2 hours, cool to room temperature, keep warm and stir for 2 hours, filter, and wash the filter cake with acetone. Dry at 75°C in vacuum to obtain 4.61g of yellow solid, with a yield of 91.2%, and the residual solvent of acetone is 0.37%, and its XRD spectrum is consistent with that in Example 1.
[0042] Example 4 Preparation of Ponatinib Hydrochloride Crystal Form A
[0043] Take 5.0g of ponatinib free base, heat and dissolve it in 150mL of ethyl acetate, then dropwise add 0.88g of hydrochloric acid and 3.5mL of N,N-dimethylformamide, stir for 30 minutes, cool to 50°C for crystallization, stir at 50°C for 2 hours, cool to room temperature, keep warm and stir for 2 hours, filter, and wash the filter cake with ethyl acetate. Dry at 75°C in vacuum to obtain 4.66g of yellow solid, with a yield of 91.5%, and the residual solvent of ethyl acetate is 0.34%. Its XRD spectrum is consistent with that of Example 1.
[0044] Comparative Example 1 Preparation of Ponatinib Hydrochloride Crystal Form A
[0045] Reference to the prior art CN104496994 A
[0058] section to prepare the synthetic route of ponatinib hydrochloride α crystal
[0046] At room temperature (about 24°C), ponatinib (5.00g) was added to 100ml acetonitrile, and the mixture was heated to 45°C and stirred for 1h. Ponatinib was insoluble; 1.04g hydrochloric acid was diluted with 10ml anhydrous ethanol and added to the mixture. The solid was dissolved and a large amount of solid precipitated after 1-2min; the mixture was stirred at 45°C for 30min, and then the mixture was cooled to 25°C, kept at 25°C and stirred for 2h, then filtered and dried at 50°C in vacuum to obtain 4.1g of off-white solid. The solvent residue of acetonitrile was 1.6%, which was much higher than the acetonitrile residue of 0.041% specified in ICH Q3C.
[0047] Compared with the preparation process of Examples 1-4 of the present application, acetonitrile is used as the solvent in Comparative Example 1. Acetonitrile belongs to a Class II solvent and is a restricted solvent. The solvent residue of acetonitrile is 1.6%, which is much higher than the acetonitrile residue of 0.041% specified in ICH Q3C; while the residual amount of the solvent used in the present application is lower than 0.5% specified in ICH Q3C; in addition, the ponatinib hydrochloride crystal form A obtained in Comparative Example 1 has poor fluidity and high static electricity, and is not suitable for pharmaceutical use.
Claims
1. A method for preparing ponatinib hydrochloride crystal form A, It is characterized in that The preparation method comprises the following steps: The ponatinib free base was heated and dissolved in ethyl acetate, and then hydrochloric acid was added dropwise, stirred for 30 minutes, cooled to 50°C, stirred at 50°C for 2 hours, cooled to room temperature, stirred at this temperature for 2 hours, filtered, and dried in vacuum at 75°C to obtain ponatinib hydrochloride crystal form A; The mass volume ratio of ponatinib free base and ethyl acetate is 1:20 to 1:50 g / mL; The X-ray powder diffraction pattern of the ponatinib hydrochloride crystal form A is substantially as shown in FIG1 .
2. The preparation method according to claim 1, It is characterized in that The molar ratio of ponatinib free base to hydrochloric acid is 1:0.8-1.1.
Citation Information
Patent Citations
New crystal form of alkyne heteroaryl compound
CN104496994A
Crystalline forms of 3-(imidazo[1,2-b] pyridazin-3-ylethynyl)-4-methyl-n-(4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl)benzamide and its mono hydrochloride salt
CN105188701A
Heteroaryl alkyne compounds and application thereof
CN103848829A
Applications and method of quinoline substance in treating thyroid and mammary gland diseases, and medicinal composition
CN106860459A
Method for the preparation of a 2,4,5-trisubstituted 1,2,4-triazolone
CN112236426A
